[go: up one dir, main page]

WO2011046991A3 - Certain substituted ureas as modulators of kinase activity - Google Patents

Certain substituted ureas as modulators of kinase activity Download PDF

Info

Publication number
WO2011046991A3
WO2011046991A3 PCT/US2010/052420 US2010052420W WO2011046991A3 WO 2011046991 A3 WO2011046991 A3 WO 2011046991A3 US 2010052420 W US2010052420 W US 2010052420W WO 2011046991 A3 WO2011046991 A3 WO 2011046991A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
compound
formula
acceptable salt
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/052420
Other languages
French (fr)
Other versions
WO2011046991A2 (en
Inventor
David R. Brittelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Connecticut Inc
Original Assignee
Gilead Connecticut Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Connecticut Inc filed Critical Gilead Connecticut Inc
Publication of WO2011046991A2 publication Critical patent/WO2011046991A2/en
Publication of WO2011046991A3 publication Critical patent/WO2011046991A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

At least one compound of Formula I or a pharmaceutically acceptable salt thereof, are provided herein. Pharmaceutical compositions comprising at least one one compound of Formula I or a pharmaceutically acceptable salt and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one compound of Formula I or a pharmaceutically acceptable salt effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one compound of Formula I or a pharmaceutically acceptable salt as a single active agent or administering such at least one compound of Formula I or a pharmaceutically acceptable salt in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one compound of Formula I or a pharmaceutically acceptable salt under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.
PCT/US2010/052420 2009-10-15 2010-10-13 Certain substituted ureas as modulators of kinase activity Ceased WO2011046991A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25198009P 2009-10-15 2009-10-15
US61/251,980 2009-10-15

Publications (2)

Publication Number Publication Date
WO2011046991A2 WO2011046991A2 (en) 2011-04-21
WO2011046991A3 true WO2011046991A3 (en) 2011-08-18

Family

ID=43876837

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/052420 Ceased WO2011046991A2 (en) 2009-10-15 2010-10-13 Certain substituted ureas as modulators of kinase activity

Country Status (1)

Country Link
WO (1) WO2011046991A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469639B2 (en) 2013-09-29 2016-10-18 Radiant Pharma & Tech. Co., Ltd. Naphthylurea derivatives and medical applications thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214479A (en) * 2012-01-18 2013-07-24 武汉东宇生物医药科技有限公司 Pyrazole naphthylurea tyrosine kinase inhibitor and its application
EP2626073A1 (en) * 2012-02-13 2013-08-14 Harmonic Pharma Compound for use in the prevention and/or treatment of a neurogenerative disease or a disease involving an activation of phosphodiesterase-4 (PDE4)
WO2015051149A1 (en) * 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof
CN104788366A (en) * 2014-01-21 2015-07-22 王若文 Raf kinase inhibitor pentafluoride sulfur-based aryl urea, and preparation method and applications thereof
CN110072526A (en) * 2016-08-17 2019-07-30 西奈山伊坎医学院 Kinase inhibitor compounds, compositions and methods for treating cancer
CN108117551B (en) * 2016-11-29 2020-03-27 华东理工大学 Substituted (1H-pyrazolo [3,4-b ] pyridine) urea compound and anti-tumor application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065838A1 (en) * 2001-02-20 2002-08-29 Reckitt Benckiser Inc Method and compositions for disinfecting hard surfaces
WO2003074005A2 (en) * 2002-03-01 2003-09-12 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2007005027A1 (en) * 2005-07-01 2007-01-11 Cell Signaling Technology, Inc. Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha
US20070232627A1 (en) * 2005-12-21 2007-10-04 Betebenner David A Anti-viral compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002065838A1 (en) * 2001-02-20 2002-08-29 Reckitt Benckiser Inc Method and compositions for disinfecting hard surfaces
WO2003074005A2 (en) * 2002-03-01 2003-09-12 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
WO2007005027A1 (en) * 2005-07-01 2007-01-11 Cell Signaling Technology, Inc. Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha
US20070232627A1 (en) * 2005-12-21 2007-10-04 Betebenner David A Anti-viral compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469639B2 (en) 2013-09-29 2016-10-18 Radiant Pharma & Tech. Co., Ltd. Naphthylurea derivatives and medical applications thereof

Also Published As

Publication number Publication date
WO2011046991A2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2005019220A3 (en) Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2011046991A3 (en) Certain substituted ureas as modulators of kinase activity
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12014500371A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
MX2015005798A (en) Combination therapy.
EP2331095A4 (en) CERTAIN KYNURENIN-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
WO2007136518A3 (en) Treatment of autoimmune disorders
WO2014205555A8 (en) Methods and uses for diagnosis and treatment of prostate cancer
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
EA201491460A1 (en) APPLICATION OF LACHINIMODA IN THE TREATMENT OF PATIENTS WITH CRONE'S DISEASE, WHICH ARE NOT EFFECTIVE THERAPY OF THE FIRST LINE ANTI-TNFα
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MA33922B1 (en) HETERAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS INHIBITORS OF ENZYME PDE10A
PH12013500142A1 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
MX2012013879A (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases.
MX2011013775A (en) A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition.
TW200639165A (en) Certain substituted ureas as modulators of kinase activity
WO2007024294A3 (en) Certain substituted ureas, as modulators of kinase activity
BR112012020185A2 (en) use of oral heparin preparations to treat urinary tract diseases and disorders.
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
Tan et al. Vagus nerve stimulation (VNS) inhibits cardiac mast cells activation and improves myocardial atrophy after ischemic stroke
UA115250C2 (en) Pharmaceutical combinations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10823984

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10823984

Country of ref document: EP

Kind code of ref document: A2